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377 Is it safe and practical to give once daily IV tobramycin to young
people with cystic ﬁbrosis at home?
C.A. Lawrence1, L.J. Heaf1, E.F. Burrows1, J.J. Cottrell1, J. Pope1,
K.W. Southern2. 1Respiratory Unit, Alder Hey Children’s NHS Foundation
Trust, Liverpool, United Kingdom; 2Child Health, University of Liverpool,
Liverpool, United Kingdom
Introduction: IV tobramycin (Tob) is associated with renal impairment and
ototoxicity, once daily (od) Tob potentially reduces these risks [1] but to ensure
that serum levels remain in the therapeutic range blood must be collected before
the ﬁrst dose (creatinine), 18−24 hours after ﬁrst dose (creatinine and Tob) and
then weekly for the duration of treatment. The results of both Tob and creatinine
levels must be checked before the next dose is administered in accordance with
our hospital aminoglycoside policy. If serum levels fall outside the accepted ranges
the dose is altered accordingly. At our unit patients receiving IV antibiotics at
home use a preﬁlled device supplied and delivered by a home care company, with
no ﬂexibility for dose adjustment. This audit aimed to assess if we had resolved
potential problems with monitoring and dose changes for patients on home IV Tob.
Method: A 12 month retrospective audit, information collected from patient notes
and hospital electronic record. Results: In a 12 month period 16 patients (age range
6−17.5 yrs) had 40 courses of od IV Tob at home. Monitoring of Tob was correct
for 36/40 after the ﬁrst dose, 19/40 a week later. Monitoring of creatinine was
correct 35/40 at the start, 6/40 after the ﬁrst dose, 18/40 a week later. All serum
Tob levels were within therapeutic range, no adverse effects on serum creatinine,
no dose adjustments were necessary and no disruption to treatment.
Discussion: This audit has identiﬁed that it is both practical and safe for patients
to have od Tob at home but staff need further education to resolve problems with
monitoring.
Reference(s)
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378 Clinical status at start of IV treatment and effect on daily life
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Background: The West Swedish CF Centre is a combined adult and pediatric
outpatient clinic with 150 patients (median age 20 yrs). All patients are seen every
4−6 weeks. Patients starting iv treatment have the ﬁrst dose at the clinic and then
continue for 10 days or more at home or in hospital with support from the CF
clinic.
Aim: To investigate how many of the patients fullﬁlled the criteria for pulmonary
exacerbation by Fuchs, the number of peripheral venous catheter (pvc) needed
during the treatment, number of days on iv, days in hospital and days sick leave
from school/work.
Method: All patients who started iv treatment during the period September 1–
December 31, 2008 at the CF center were included. Thirty-six patients had a
follow up at the end of treatment while 11 patients stopped treatment at home
after telephone consultation with the nurse.
Results: Forty patients (20F, median age 23, range 6−66 yrs) started a total of 47
iv treatments. Seven started two iv treatments during the period. FEV1.0 at start
was 64±20%, 25 were chronically colonized with PA and 20 had iv subcutaneous
devices while 27 used pvc. Two patients spent 9 and 4 days respectively in hospital.
The median length of iv was 10 days, only 7 patients extended the treatment up to
15 days. Only 10/47 patients fulﬁlled Fuchs criteria at start. Five of 15 children were
absent from school /daycare center (median 9, range 2−10 days). Of 31 iv treatments
in adults, 16 were absent from work/studies (median 10, range 3−10 days). The
median number of pvc used per patient were 2 (range 1−6). FEV1.0 improved by
5.7±6.4%, n 0.001, while weight was unchanged.
Conclusion: Only 25% fulﬁlled Fuchs criteria. The two who were hospitalized for
i.v.treatment was treated for the ﬁrst time. More than 50% of the patients continued
to work /go to school as usual.
379 Peripherally Inserted Central Catheter (PICC) for home IV therapy:
a Belgian CF center experience
F. Wustefeld1, T. Pirotte1, F. Veyckemans1, G. Reychler1, A. Leonard1,
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Background: Many (mostly adult) CF patients need repeated IV antibiotic treat-
ments. Implanted ports and CVCs are commonly used in Europe but complications
such as pneumothorax, infection and thrombosis are reported. We evaluated PICCs
as an alternative without risk of pneumothorax, in terms of success rate, thrombo-
genicity, infection and safety for home IV therapy.
Methods: From March 2007 to January 2009, 60 PICCs were placed in 33
CF patients (age 27.6 y ± 10.6, 15 M, FEV1= 59% pred ± 20.2). PICCs were
inserted under ultrasound guidance at midhumeral level. Maintenance at home was
performed by a dedicated CF nurse. PICC insertion process, related complications,
and patient satisfaction were prospectively recorded.
Results: PICCs were successfully placed in 55/60 insertions (91%). Insertion
failures occurred exclusively in women. Therapy was completed with 1 PICC in
53/55 treatments (96%). Among these, satisfaction evaluated on a visual analogic
scale (1−5) was high (4.9/5). Median duration of treatment was 16 days (total: 957
PICC days, 1−6 treatments/patient). One major complication (catheter embolism)
occurred; another PICC was removed prematurely by home doctor because of
leakage. Following minor complications did not interfere with completion of
therapy: local phlebitis (1.8%), haematoma (9%), local bleeding (9%) and local
pain (12%). No infection nor occlusion were noticed.
Conclusion: PICC lines are safe and convenient to infuse IV antibiotics in CF
patients at home. Mechanical complications are reduced with expert insertion and
an adequate maintenance.
Supported by: Association Belge de Lutte contre la Mucoviscidose (ABLM).
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There are 100,000 reported incidences of needlestick injuries in the NHS healthcare
system each year, but the overall incidence is almost certainly higher as many
go unreported.(www.needlestickforum.net Safer needles network 2006). As well
as the threat of blood borne diseases, needle stick injuries also result in anxiety
for the nurse, her family and the patient who has to be tested according to the
hospital protocol. Implanted portacaths are widely used in the Cystic Fibrosis patient
population. Access to the port is performed with the percutaneous insertion of a non
coring needle into the port reservoir. When the needle is withdrawn there is often a
degree of resistance as the needle comes out of the silicone septum. The area around
the port is supported with a gloved hand due to potential resistance. The hand is then
in a hazardous position due to the proximity of the needle and rebound injuries are
common. It is estimated that 47% of accidental needlestick injuries from portacath
needles are due to this rebound effect when withdrawing needles from the implanted
port. (Stoker R: To the point: Safety Huber Needles: Managing infection control
Dec 2003). It became essential that a method of prevention be sought and that the
technology is available to remove the threat. The existing products were evaluated
and did not meet our clinical need and therefore a modiﬁcation was developed
locally. We have produced a safety device that is user friendly, inexpensive to
manufacture and imposes no extra discomfort to the patient. It is well recognised
that the NHS has a legal duty of care to employees and invest in safer devices when
available. In this case the cost to the NHS would be minimal, but the beneﬁts of
avoided injury would be considerable.
